Can Prebiotics Support Microbial Metabolic Function Following Low-FODMAP Restriction in Irritable Bowel Syndrome?
- 1Institute of Clinical Physiology, National Research Council, Via Moruzzi 1, 56124 Pisa, Italy
- 2Institute of Agricultural Biology and Biotechnology, National Research Council, Via Moruzzi 1, 56124 Pisa, Italy
Abstract
Irritable bowel syndrome (IBS) is one of the most common disorders of gut–brain interaction, and dietary interventions play a central role in symptom management. Among these, the low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP) diet has been shown to improve abdominal pain, bloating, and altered bowel habits in a substantial proportion of patients. However, restriction of fermentable carbohydrates may reduce the availability of substrates for the gut microbiota and has been associated with reductions in selected microbial taxa, including Bifidobacterium, raising questions about its effects on microbial ecology and metabolism. Dietary prebiotics selectively stimulate gut microorganisms and promote microbial fermentation and the production of metabolites, including short-chain fatty acids, that may contribute to intestinal homeostasis. However, many prebiotics are also highly fermentable substrates, and their gastrointestinal effects may vary substantially among individuals with IBS. This creates a challenge in balancing symptom control with continued exposure to substrates that may support microbial and metabolic functions. In this narrative review, we critically examine the metabolic and clinical implications of dietary prebiotics in IBS, with particular emphasis on their potential role following low-FODMAP restriction. We discuss their effects on gut microbiota composition and function, microbial metabolites, and clinically relevant outcomes, with particular attention to the relationship between microbial and symptomatic responses. We further consider the potential role of structured reintroduction and personalization of tolerated fermentable substrates in maintaining dietary variety and microbial substrate availability while minimizing gastrointestinal symptoms. Finally, we discuss interindividual variability in responses to fermentable substrates and factors that may contribute to differential responses, highlighting current limitations in linking microbiota composition, microbial function, metabolite production, and clinical outcomes in IBS, and identifying possible directions for future research.
Related
- Isocaloric restriction of a high-fat diet under TAK-242 administration: metabolic and gut microbial responses in mice
- Gut microbial functional associations with subsequent irritable bowel syndrome in a prospective, paediatric case–control study
- Longitudinal Multi-omics Reveals Persistent Gut Microbial and Metabolic Dysbiosis Following Anti-Tuberculosis Therapy
- Cortical and basal ganglia diffusion restriction following benzodiazepine overdose: An unusual MRI pattern of evolving hypoxic–ischemic encephalopathy
- Sustained Maternal Cortisol Elevation Links Metabolic Stress to Fetal Growth Restriction in a Guinea Pig Model of Undernutrition
BibTeX
@article{gorini2026prebiotics,
title = {{Can Prebiotics Support Microbial Metabolic Function Following Low-FODMAP Restriction in Irritable Bowel Syndrome?}},
author = {Francesca Gorini and Alessandro Tonacci and Morena Gabriele and Andrea Borghini},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18213535},
url = {https://www.mdpi.com/2072-6643/18/21/3535},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Can Prebiotics Support Microbial Metabolic Function Following Low-FODMAP Restriction in Irritable Bowel Syndrome?
AU - Francesca Gorini
AU - Alessandro Tonacci
AU - Morena Gabriele
AU - Andrea Borghini
PY - 2026
DA - 2026/10/27
JO - Nutrients
DO - 10.3390/nu18213535
UR - https://www.mdpi.com/2072-6643/18/21/3535
AB - Irritable bowel syndrome (IBS) is one of the most common disorders of gut–brain interaction, and dietary interventions play a central role in symptom management. Among these, the low-fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low-FODMAP) diet has been shown to improve abdominal pain, bloating, and altered bowel habits in a substantial proportion of patients. However, restriction of fermentable carbohydrates may reduce the availability of substrates for the gut microbiota and has been associated with reductions in selected microbial taxa, including Bifidobacterium, raising questions about its effects on microbial ecology and metabolism. Dietary prebiotics selectively stimulate gut microorganisms and promote microbial fermentation and the production of metabolites, including short-chain fatty acids, that may contribute to intestinal homeostasis. However, many prebiotics are also highly fermentable substrates, and their gastrointestinal effects may vary substantially among individuals with IBS. This creates a challenge in balancing symptom control with continued exposure to substrates that may support microbial and metabolic functions. In this narrative review, we critically examine the metabolic and clinical implications of dietary prebiotics in IBS, with particular emphasis on their potential role following low-FODMAP restriction. We discuss their effects on gut microbiota composition and function, microbial metabolites, and clinically relevant outcomes, with particular attention to the relationship between microbial and symptomatic responses. We further consider the potential role of structured reintroduction and personalization of tolerated fermentable substrates in maintaining dietary variety and microbial substrate availability while minimizing gastrointestinal symptoms. Finally, we discuss interindividual variability in responses to fermentable substrates and factors that may contribute to differential responses, highlighting current limitations in linking microbiota composition, microbial function, metabolite production, and clinical outcomes in IBS, and identifying possible directions for future research.
SN - 2072-6643
ER -